[
    "{\"step_by_step_thinking\": \"Isradipine is a calcium channel blocker that was hypothesized to have potential neuroprotective effects in Parkinson's disease. However, the STEADY-PD III trial, a large, multicenter, randomized, placebo-controlled, double-blind clinical trial, found that isradipine did not slow the progression of symptoms in early Parkinson's disease.\", \"answer_choice\": \"B. no\"}"
]